Experience with cladribine tablets for highly active multiple sclerosis in real clinical practice

Objective : to evaluate the efficacy and safety of cladribine tablets as a treatment for immune reconstitution highly active multiple sclerosis (HAMS) in general clinical practice. Patients methods . 34 patients with HAMS who were followed up at Moscow Multiple Sclerosis Center 2018–2021 received two full courses. diagnosis was established presence or more exacerbations per year without one exacerbation receiving pathogenetic concomitant manifestations activity pathological process on MRI. Before initiation therapy, median rate 2.3 year, i.e., had total 78 exacerbations. Results discussion Only registered (one each first second year) during years among all patients, average frequency 0.05 year; three cases, subclinical noted - new Gd+ lesions T2-weighted images MRI, number events 0.15 year. No significant adverse reported. Conclusion Cladribine are effective safe option HAMS.